BIOCHINA 2026 will provide companies with a platform to showcase their 2025 milestones to over 30,000 biopharma professionals in China. The initiative is designed to highlight significant accomplishments in the biopharmaceutical industry and offer enhanced visibility in China’s growing market.

Companies are encouraged to submit achievements such as:

New drug approvals

Successful product launches

Breakthroughs in research and development

Major new clients or orders

Industry awards or recognition

By participating, companies can strengthen their brand presence, demonstrate innovation, and engage with key stakeholders in China’s dynamic biopharma ecosystem.

Submissions are now open:

http://biocn.cn/7a